Peer-reviewed discovery platform and data in PNAS show that single transcription factor modulation reverses aging-associated gene expression and restores healthy cellular and tissue function in models ...

Bayer and Soufflé Therapeutics™, an innovative biotech company that discovers and develops cell-selective genetic therapies, ...

Bayer AG enters into collaborations to develop a heart-targeted siRNA therapy and AI technology, expanding its push into next ...

Generation Bio Co. is developing siRNA therapeutics for T cell-driven autoimmune diseases using its T cell-selective lipid nanoparticle technology. This innovative delivery system aims to effectively ...

CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today highlighted its strategic priorities and anticipated ...

The companies will leverage Bayer's expertise in developing medicines for heart conditions and Soufflé's siRNA delivery technologies to advance the treatment.

Table 2. Stable nucleic acid lipid particle formulations. Stable nucleic acid lipid particle formulations in systemic delivery Target siRNA and modification (yes/no) Animal model Ref.

PeptiDream and Alnylam Announce Achievement of Key Milestone in siRNA Conjugate Discovery Collaboration Demonstrating Peptide-Ligand Mediated Targeted siRNA Delivery to Specific Extrahepatic Tissues ...

Bayer & Soufflé Therapeutics enter strategic collaboration to advance cell-specific heart-targeted siRNA therapy: Berlin, Germany Friday, January 9, 2026, 09:00 Hrs [IST] Bayer a ...